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1. Introduction
Chronic liver disease of any aetiology can result in portal hypertension. Portal hypertension
leads to the formation of porto-systemic collaterals including gastro-oesophageal varices.
The development of portal hypertension can also herald the development of other complica‐
tions of liver cirrhosis such as ascites formation, hepatic encephalopathy and when varices
occur, their bleeding. However it should be noted that portal hypertension also occurs in
non-cirrhotic conditions, such as: Budd-Chiari, myeloproliferative diseases and extra-hepat‐
ic portal vein obstruction.
Variceal  haemorrhage  is  a  serious  life-threatening  complication  of  portal  hypertension,
with overall mortality rates historically reported as 30-50% [1]. Although mortality can be
up to  40% at  6  weeks,  it  can be up to  70% at  1  year  [2].  With the generally  improved
management  of  the  critically  ill  cirrhotic  patient,  together  with  vasoactive  therapy  and
new endoscopic techniques for managing variceal haemorrhage, overall mortality has re‐
duced, with one centre in Europe showing a reduction from 42% in 1980 to 14% in 2000
[3]. The treatment of gastric varices has also evolved over recent years with the introduc‐
tion of  adhesive compounds such as  N-butyl-2-cyanoacrylate  and thrombin,  and the in‐
creased use of Transjugular Intrahepatic Portosystemic Shunts (TIPS) in variceal bleeding
and early in rebleeding. New self-expanding oesophageal stents have been developed for
oesophageal haemorrhage in the ever expanding endoscopic armamentarium against vari‐
ceal  bleeding.  Earlier  emergency access to endoscopy performed by skilled endoscopists
has coincided with the decline in use of tamponade equipment such as Sengstaken-Blake‐
more tubes,  and the virtual  extinction of  emergency surgical  procedures of  oesophageal
transection or porto-caval shunt formation.
© 2013 Rajoriya and Gorard; licensee InTech. This is an open access article distributed under the terms of the
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This chapter addresses the aetiology and pathogenesis of oesophageal and gastric varices,
the strategy of primary prophylaxis against variceal bleeding, and reviews the medical and
endoscopic treatment of variceal haemorrhage and rebleeding thereafter.
2. Portal hypertension and the development of varices
Portal hypertension is a key factor in the development of oesophageal or gastric varices. The
endoscopic appearances of oesophageal and gastric varices can be seen in Figures 1 and 2
respectively.
Figure 1. Quiescent column of oesophageal varices
Figure 2. Gastric varix seen on retroflexion of the endoscope in fundus of the stomach with the classical “hanging
grapes” appearance (courtesy of Dr Branislav Kunčak, University of Trnava and Nové Zámky Hospital, Nové Zámky, Slo‐
vakia at www.Endoatlas.sk)
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The portal pressure is the pressure in the portal vein and portal vein tributaries. Normal
portal pressure is 1-5 mmHg. When the portal pressure gradient (difference in pressure be‐
tween the pressure in the portal vein and hepatic vein) exceeds 10-12mmHg, varices will
form. The causes of portal hypertension categorised by anatomical site are summarised in
Table 1.
SITE CAUSES
PRE-HEPATIC Portal vein/ splenic vein thrombosis
Extrinsic compression of portal vein
Portal vein congenital abnormalities (stenosis)
INTRA-HEPATIC Any cause of cirrhosis (alcoholic, metabolic, viral, biliary, autoimmune)
Acute alcoholic hepatitis
Veno-occlusive disease
Hepatocellular carcinoma
Chronic active hepatitis
Acute fatty liver of pregnancy
Amyloidosis
Chronic Hypervitaminosis A
Polycystic disease
Nodular regenerative hyperplasia
Granulomatous liver diseases (TB, sarcoidosis, schistosomiasis)
POST-HEPATIC Tricuspid valve disease / severe right heart failure
Constrictive pericarditis
Inferior vena cava thrombosis/ congenital malformations
Hepatic vein thrombosis (Budd Chiari)
Table 1. Causes of portal hypertension related to site of increased resistance to portal blood flow
Irrespective of the site of resistance to portal blood flow, there are different mediators in‐
volved in the development of portal hypertension as outlined in Figure 3.
Portal hypertension can develop from structural changes within the liver, altering the archi‐
tecture and thus leading to distortion of the blood flow through the liver. This results in in‐
creased vascular resistance. Such structural changes are the main cause for increased
intrahepatic vascular resistance. Nodule generation, sinusoidal capillarization (development
of a basal membrane around the sinusoid in the Space of Disse and fibrous tissue accumula‐
tion), sinusoidal collapse and hepatocyte enlargement all lead to shrinking and narrowing of
the sinusoid unit leading to increased intrahepatic vascular resistance. Once these pathologi‐
cal changes occur, they can be an irreversible / fixed component of the development of por‐
tal hypertension. Depending on the aetiology and thus treatment of disease, degrees of
fibrosis can in some cases be partially reversed.
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Figure 3. Overview of the mechanisms in the development of portal hypertension. (NO = nitric oxide)
Activated hepatic stellate cells (HSCs) are key mediators in the production of peri-sinusoidal
hepatic fibrous tissue and the laying down of extracellular matrix [4]. Such deposition of fi‐
brous tissue around the sinusoids can be the initial event in sinusoidal capillarization [5]–
whereby extracellular matrix is deposited in the Space of Disse, and furthermore this can re‐
sult in sinusoidal endothelial cells producing less nitric oxide (NO), which activates HSCs
further. Any underlying liver disease promoting a fibrosis architecture of the liver can lead
to portal hypertension [6]. As the fibrosis persists and progresses, liver cirrhosis can ensue.
The development of portal hypertension leading to collateral formation and varices relies not
only on structural changes within the liver, but also on increased vascular tone within the liv‐
er. The alterations in vascular tone are dynamic changes. The HSCs are activated and can con‐
strict as fibrosis and cirrhosis develop leading to a further vasoconstriction at the sinusoidal
level. The mechanisms by which this occurs are multifactorial but include a change of HSC
from a quiescent phenotype to a myofibroblast-like phenotype [6], which has greater contrac‐
tile properties, and an up-regulation of calcium-channel receptors that mediate constriction [6,
7]. In addition to the activation of HSCs, there is an increase in mediators of vasoconstriction
including Thromboxane A2, Angiotensin II, RhoA, endothelin, and eicanosoid, which have
been shown at experimental level to increase intravascular intrahepatic tone [8-11]. The in‐
crease in vasoconstrictors is coupled with a reduction of vasodilators such as homocysteine
and NO, with the latter being a key mediator in portal circulation vasodilatation [12] and in the
formation of collateral vessels [13,14]. The production of NO is promoted by vascular endothe‐
lial growth factor, which also promotes porto-collateral vessel formation [15].
Vasodilatation of the arterial splanchnic vessels is an important factor in the development of
portal hypertension. Chronic vasodilatation leads to increased blood flow to the porto-ve‐
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nous system and development of porto-systemic collateral formation and varices [16]. In‐
creased portal pressure is the most important risk factor for the development of varices [2].
Varices develop once a hepatic venous pressure gradient (HVPG), a surrogate marker for si‐
nusoidal portal hypertension, exceeds 10-12mm Hg [17]. Lowering the portal pressure is a
key target in the prevention of variceal formation, in the prevention of variceal bleeding,
and in the management of acutely bleeding varices [18]. One other major feature in portal
hypertension is the development of the hyperdynamic circulatory syndrome, which is asso‐
ciated with the development of varices [16]. This is characterised by a decreased mean arte‐
rial pressure, increased cardiac output and decreased systemic vascular resistance. The
hyperdynamic circulation again is a target for drug therapies including beta-blockers to re‐
duce portal hypertension, with the main driver for the vasodilatation and subsequent hyper‐
dynamic circulation being NO [16].
3. Growth, classification and location of varices
Once portal hypertension ensues, there is development of porto-systemic collateral forma‐
tion in an attempt to decompress the rising portal pressure. Two basic mechanisms lead to:
(1) neo-angiogenesis and (2) dilatation of pre-existing embryonic channels between the por‐
tal and systemic circulations [19, 20]. Gastro-oesophageal varices develop as part of cepha‐
lad collaterals formed after dilatation of the left gastric (coronary) vein and the short gastric
veins. Once established, varices can remain indolent or grow in size, and also cause life-
threatening haemorrhage. When the portal pressure is above 10 mmHg, the median time for
the development of varices is 4 years [21] while some studies show a de novo formation rate
of 4-6% per year [22, 23].
Variceal size is a predictor of haemorrhage, as predicted by La Place’s law, whereby wall
tension increases with variceal radius and transmural variceal pressure. The mean risk of
haemorrhage from larger varices (>5mm) is 30% at 2 years, compared to 10% from small
varices at 2 years [24,25]. Risk factors for the dilatation of varices include: an increase in por‐
tal pressure [26], alcohol consumption [27], circadian rhythm [28], prandial blood flow
bursts [29] and also Child-Pugh class at baseline and its deterioration during follow-up [30,
31]. The rate of yearly increase in size of varices varies from a range of 8% to 31% [32,
33].The two main locations of varices that may rupture are the lower oesophagus and the
stomach.
3.1. Oesophageal varices
Oesophageal varices are long columns of dilated veins (Figure 1), usually occurring within the
lower third of the oesophagus, immediately above the gastro-oesophageal junction (GOJ). Oe‐
sophageal varices can be graded endoscopically according to size [34] (Table 2/ Figure 4), while
the American Association for the Study of Liver Diseases (AASLD) recommends the classifica‐
tion into small and large oesophageal varices based on a cut-off of 5mm [35].
Endoscopic Management of Oesophageal and Gastric Varices
http://dx.doi.org/10.5772/52524
103
GRADE OF OESOPHAGEAL VARIX DESCRIPTION
1 (small) Small straight varices
2 (medium) Enlarged tortuous varices occupying less than one third of the
lumen
3 (large) Large coil-shaped varices occupying more than
one third of the lumen
Table 2. Grading of oesophageal varices according to Italian liver cirrhosis project. (Reference 34)
Figure 4. Grading of oesophageal varices endoscopically (adapted from reference 24)
The major blood supply to oesophageal varices is from the left gastric vein. There are 4 lay‐
ers of veins in the oesophagus (Figure 5). The intra-epithelial veins are the most superficial
veins and correlate with the red spots seen at time of endoscopy. These red spots have been
shown to be predicative of variceal rupture (along with variceal size and Child-Pugh class
[25]). Deeper to these veins is the superficial venous plexus, which then drains into deeper
intrinsic veins. These in turn are then connected via perforating veins to the deepest adven‐
titia plexus. It is the main trunks of the deep adventitia plexus that large oesophageal varices
arise from.
An area of common oesophageal variceal rupture is at the GOJ - the palisade zone – an area of
venous tributaries between the gastric zones and perforating zone (in the oesophagus). This
area is a watershed between the azygous and portal blood flow systems, where venous flow is
bidirectional with turbulent flow – which may explain frequent rupture [36] – and thus why
when banding, oesophageal bands should be applied as close to the GOJ as possible.
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Figure 5. The anatomy of veins within the oesophagus from which oesophageal varices arise.
3.2. Gastric varices
Gastric varices are supplied by the short gastric veins, draining into the deep intrinsic veins
of the lower oesophagus, and can be classified according to site by the Sarin classification of
gastric varices [37] (Figure 6 / Table 3).
Figure 6. Sarin classification of gastric varices (adapted from reference 37)
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Gastric varices account for 10-30% of variceal haemorrhage and can occur in up to 20% of pa‐
tients with portal hypertension [17, 38]. Management of bleeding gastric varices differs from
that of the more common situation of bleeding oesophageal varices (see later in chapter).
SARIN TYPE OF GASTRIC VARIX DESCRIPTION/LOCATION
Gastro-Oesophageal Varices -1 (GOV-1) Continuation from oesophageal varices and extend on lesser curve
Gastro-Oesophageal Varices -2 (GOV-2) Extend along lesser curve and more tortuous than GOV-1
Isolated Gastric Varices-1 (IGV-1) Occur in absence of oesophageal varices, and occur in the fundus, and are
tortuous and complex
Isolated Gastric Varices-2 (IGV-2) Occur in absence of oesophageal varices, in the body, antrum or pylorus
Table 3. Sarin classification of gastric varices (adapted from reference 37).
4. Prevention of 1st variceal haemorrhage – Primary prophylaxis
Since patients with cirrhosis may have portal hypertension and varices, there is a rationale
for screening of such patients to identify those with varices who might benefit from primary
prophylaxis against variceal haemorrhage. Thus those patients who have a diagnosis of cir‐
rhosis either clinically, biochemically or on liver biopsy, should be offered Oesopho-Gastro-
Duodenoscopy (OGD) looking for gastro-oesophageal varices [39]. When cirrhosis is
diagnosed, any factors causing the continuing insult to the liver must be addressed – such as
treatment of the underlying condition (e.g. viral /autoimmune or ongoing alcohol intake in
alcoholic liver disease). In those cirrhotic patients who do not have varices diagnosed on ini‐
tial endoscopy, a follow up endoscopy has been recommended after 2-3 years [40] particu‐
larly if hepatic synthetic function worsens (i.e. worsening in Child-Pugh status). Primary
prophylaxis aims to prevent variceal haemorrhage in patients who have varices but who
have not had a previous bleeding episode. Strategies used in primary prophylaxis can be
broadly divided into pharmacological and endoscopic therapies.
4.1. Pharmacological therapies as primary prophylaxis
Drug therapies are used to prevent variceal bleeding, and if well tolerated by patients can be
effective. Isosorbide mononitrate (ISMN) is a potent vasodilator used in ischaemic heart dis‐
ease and reduces vascular tone. There are theoretical reasons why ISMN should help to pre‐
vent variceal bleeding. In randomised control trials ISMN has been shown to reduce HVPG
by 7.5% [41,42], and to augment the splanchnic vasoconstrictive effects of the non-selective
beta-blocker propranolol [42]. It has been used when there are contra-indications to, or intol‐
erance of beta-blocker drugs in patients with varices. However a double-blind randomised
controlled trial in patients intolerant of beta-blockers, compared ISMN with placebo and
found that ISMN was ineffective at preventing a first variceal bleed [43].
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Non-selective beta-blockers are the mainstay of treatment in the prevention of variceal
bleeding once varices have been identified. Non-selective beta-blockers not only block be‐
ta-1 receptors, reducing cardiac output and thus portal blood flow, but also block the adre‐
nergic dilatory tone in the mesenteric arterioles, resulting in unopposed alpha-adrenergic
vasoconstriction and a decrease in portal blood flow [44]. Nadolol or propanolol can reduce
HVPG measurements by up 10% [45,46] and are effective in reducing variceal bleeding rates
and mortality when compared to placebo [47,48]. Their roles have been firmly established in
guidelines [2,35] with the choice between them dependent on institutional practice. Carvedi‐
lol is a potent non-selective beta-blocker, with weak vasodilating effects due to alpha-1-
blockade [49]. This leads to a reduction in hepatic vascular tone and hepatic resistance [50].
Carvedilol has been shown in multiple studies to reduce portal pressure and HVPG signifi‐
cantly more than propranolol [51-54], but its role in primary prophylaxis is not yet been es‐
tablished [2]. Once beta-blocker therapy has been instituted, patients with varices who are
compliant with their medication do not require further endoscopy unless bleeding occurs.
However some US centres prefer to repeat endoscopy annually in varices patients on beta-
blockers and consider changing to a programme of endoscopic variceal band ligation
(EVBL) if the varices increase in size. This latter strategy, however, is non-evidence based.
Side-effects of beta-blockers include bronchoconstriction, heart failure and impotence, and
these can often limit a patient’s tolerability of the drug. The safety of beta-blockers in cir‐
rhotic patients with refractory ascites has also been questioned in a prospective study of 151
patients in such a cohort [55]. The 1-year probability of survival was significantly lower in
patients who received propranolol [19% (95% CI = 9%-29%)] versus those who did not [64%
(95% CI = 52%-76%), p< 0.0001]. Further studies in this area are required as this initial study
was not a randomised controlled trial. It has been postulated that beta-blockers are only
beneficial during a set time window in the progression of cirrhosis with portal hypertension
[56]. There may be no benefit in early cirrhosis when there is less risk of bacterial transloca‐
tion, no increase in sympathetic nervous system activity and when the cardiac compensato‐
ry reserve remains intact. However as cirrhosis progresses with increasing bacterial
translocation and increased sympathetic nervous system activity, there is an increased risk
of variceal haemorrhage, and beta-blockers become beneficial in not only reducing variceal
bleeding but also reducing bacterial translocation. The window then closes in advanced cir‐
rhosis as beta-blockers exert a negative impact on cardiac compensatory reserve.
4.2. Endoscopic therapies as primary prophylaxis
Endoscopic treatments can be used to obliterate/thrombose oesophageal varices. Injection
sclerotherapy involves the injection of a sclerosant (usually ethanolamine) via a needle-cath‐
eter directly into a varix to thrombose it. Although intuitively the obliteration of varices be‐
fore they have a chance to bleed would seem to be a logical strategy, injection sclerotherapy
is not without complication. In fact when sclerotherapy for primary prophylaxis against var‐
iceal bleeding was formally studied in a randomised trial, patients with varices randomised
to sclerotherapy had a higher mortality than patients with varices in the control arm [57].
Consequently injection sclerotherapy should not be used as primary prophylaxis against
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variceal bleeding. Injection sclerotherapy for oesophageal varies has largely been supersed‐
ed by EVBL in the past 2 decades. EVBL is an alternative to non-selective beta-blockers, in
those intolerant to the medication or for those often with medium or large varices (Figure 7).
EVBL should be performed by an endoscopist who has expertise in variceal band ligation to
minimise complications in day-case endoscopy patients.
EVBL can be used to treat acutely or recently bleeding oesophageal varices, or can be per‐
formed electively to obliterate varices and thus prevent bleeding or rebleeding. Once a diag‐
nostic OGD has been performed and has identified oesophageal varices, the most distal level of
variceal location is noted, and the endoscope removed. A single-use, multiband ligator incor‐
porating up to 10 bands, is then loaded onto the endoscope. A cap fitting over the endoscope’s
tip holds the mounted bands, and is connected through the accessory port of a standard endo‐
scope, with the firing handle mounted close to the endoscope’s operating wheels. Once the li‐
gator has been loaded onto the endoscope, the oesophagus is re-intubated. The ligator’s cap
may make intubation and subsequent endoscopic views a little more difficult.
The first varix to be banded should be the largest one with stigmata of recent/active haemor‐
rhage, or if quiescent then the most distal varix just above the GOJ, since varices at/just
above the GOJ are those most likely to bleed. Furthermore, if a proximal varix is banded
first, it may be difficult to then pass the endoscope beyond it without dislodging the band.
Suction is applied, aspirating the varix into the cap, until the varix is completely sucked up
(as seen by a red-out on the screen). Operating the firing handle releases a band onto the
varix neck, and release of suction allows the banded varix to be viewed (Figure 7). There‐
after, additional variceal banding can be continued in a cranial direction. Complications of
EVBL include band-induced ulceration (which may present as a re-bleed requiring urgent
endoscopy), transient dysphagia or chest pain, and rarely oesophageal stricturing.
Figure 7. Endoscopic variceal band ligation of oesophageal varices (courtesy of Dr Branislav Kunčak, 2nd Dept. of In‐
ternal Medicine, Faculty of Health and Social Work, University of Trnava and Nové Zámky Hospital, Nové Zámky, Slova‐
kia. at www.Endoatlas.sk)
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The role of EVBL in patients with medium or large varices has been studied in several trials,
and has also been compared to beta-blockers. Meta-analyses show that for primary prophy‐
laxis, both beta-blockade and EVBL have similar efficacy and mortality [53, 58-63]. Guide‐
lines currently do not recommend combination therapies with both EVBL and non-selective
beta-blockers [2,35,40]. Local factors including availability of endoscopic procedures, and
technicians able to perform EVBL may influence choices between beta-blockade and EVBL
as primary prophylaxis. The cost of endoscopy with EVBL is higher than the cost of beta-
blocker medication, particularly since banding programmes require follow-up endoscopies
to ensure variceal eradication (with up to 22% recurrence post-EVBL reported in one study
[59]). Guidelines recommend EVBL every 1-2 weeks after initial OGD until the varices are
obliterated, and then 6-12 monthly check endoscopies [35].
Current Baveno V guidelines on portal hypertension [2] recommend primary prophylaxis
with non-selective beta-blockers for patients with small oesophageal varices and red wale
marks or Child C cirrhotic patients. These guidelines also suggest that patients with small
oesophageal varices but without signs of increased risk of haemorrhage or Child C cirrhosis
could be considered for treatment with non-selective beta-blockers, although further studies
are necessary. Patients with medium or large oesophageal varices can be treated with either
beta-blockers or EVBL. Current American Association for the Study of Liver Diseases
(AASLD) guidelines [35] similarly recommend prophylaxis with non-selective beta-blockers
for patients with compensated cirrhosis and small oesophageal varices with or without fea‐
tures of likely increased haemorrhage risk. The AASLD guidelines also recommend non-se‐
lective beta-blockers or EVBL for those with medium or large varices.
For gastric varices, injection of N-Butyl-2-Cyanoacrylate glue has been studied in the pri‐
mary prophylaxis setting. This long-chain cyanoacrylate glue polymerises and solidifies
within seconds following contact with aqueous media such as blood within a varix. This
leads to obliteration of the varix from which the cast extrudes after 2-4 weeks. Mixing the
cyanoacrylate with the oily agent Lipiodol delays polymerisation. The glue treatment was
compared with beta-blockers or no therapy in a randomised controlled trial [64], with signif‐
icantly reduced probabilities of bleeding in patients treated with glue compared to beta-
blockers or no therapy (13% v 28% and 45% respectively). However the use of the glue for
gastric varices has complications (see later in chapter in “Endoscopic treatment of acute gas‐
tric variceal haemorrhage” section) and its role in primary prophylaxis against gastric vari‐
ceal bleeding has not yet been established [2]. Although there is a paucity of data from
prophylactic studies on gastric variceal bleeding, there is current consensus that using beta-
blockers to reduce portal pressure is appropriate in this setting [2].
5. General management strategies in acute variceal haemorrhage
Variceal haemorrhage is a life-threatening emergency with a mortality of 20-40% at 6-weeks
(65). Factors predictive of death within 6 weeks of index bleeding in patients with cirrhosis in‐
clude: site of bleed is varices (instead of other pathology), level of bilirubin, underlying alco‐
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holic liver disease, presence of encephalopathy or coagulopathy and the need for balloon
tamponade [2,40,65]. If haematemesis or melena occurs in patients known to have cirrhosis or
stigmata of chronic liver disease, variceal bleeding should be considered. AASLD guidelines
recommend such patients should be managed in an intensive care setting [35]. Tracheal intuba‐
tion should be considered if the patient has a reduced Glasgow Coma Scores (GCS) or signs of
hepatic encephalopathy, since these increase the risk of aspiration. Furthermore, subsequent
endoscopy to diagnose and treat the bleeding point is safer in an intubated patient. General
measures include wide-bore venous access or central venous access, and fluid resuscitation
with either colloid or blood products. Blood resuscitation to maintain a haemoglobin level of
approximately 8g/dl has been recommended [40], as experimental studies have shown the to‐
tal restoration of all lost blood may raise portal pressure higher than that of baseline [66], with
subsequent higher rates of re-bleeding and mortality [67]. There must however be adequate ar‐
terial pressure to maintain renal perfusion (and prevent acute kidney injury and the develop‐
ment of hepato-renal syndrome). Clotting and platelet deficiencies should be corrected.
Bacterial infections are common in cirrhotic patients, and antibiotics have been shown to re‐
duce bacterial infections, recurrent bleeding and mortality in patients bleeding from oeso‐
phageal varices [68,69]. Broad-spectrum antibiotic prophylaxis is recommended [35]. Local
antibiotic policy and a patient’s nil-by-mouth status are important influences, but the antibi‐
otic used should be either an oral quinolone, or else a 3rd generation intravenous cephalo‐
sporin in patients who have advanced cirrhosis, or previously received quinolone
prophylaxis, or live in areas of high quinolone resistance [2].
Figure 8. Bleeding oesophageal varices (courtesy of ELLA-CS, Hradec Kralove, Czech Republic)
The use of vasoactive drugs to lower portal pressure is paramount in the initial management of
variceal bleeding. Such drugs should be given prior to endoscopy if the source of upper gastro‐
intestinal bleeding is suspected to be varices [2, 70]. Vasopressin and terlipressin cause con‐
striction of the splanchnic arterioles, thus leading to increased resistance to inflow of blood to
the gut. This leads to a lowering of portal venous pressure. Side effects however include myo‐
cardial ischaemia and these vasoconstrictors are contraindicated in peripheral vascular dis‐
ease. Vasopressin has been shown to achieve haemostasis in 60-80% of patients, but has limited
effects on reducing early rebleeding and does not improve survival from active variceal hae‐
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morrhage [71]. Vasopressin has largely been superseded by terlipressin in countries where it is
available (not the USA). Terlipressin (triglycyl-lysine vasopressin) is a synthetic analogue of
vasopressin administered at an initial dose of 2mg, then 1mg intravenously every four hours.
Meta-analysis shows that terlipressin reduces all-cause mortality when compared to placebo
[71, 72] and it should be instituted early and continued for up to 5 days, as this is the period
during which rebleeding is common. When compared to somatostatin analogues such as oc‐
treotide, the haemodynamic effects of terlipressin on portal pressure are more sustained [73],
suggesting terlipressin may have a more prolonged benefit in bleeding varices.
Somatostatin and somatostatin analogues (e.g. the long-acting analogue octreotide) act by
increasing splanchnic arterial resistance, and inhibit vasoactive peptides such as glucagon.
Octreotide is used as first-line vasoactive therapy in the USA (where terlipressin is unavaila‐
ble). It is given intravenously as a 50 microgram bolus followed by a continuous infusion of
50 micrograms per hour. Octreotide causes a transient reduction in portal pressure and azy‐
gous blood flow lasting up to only 5 minutes despite continuous infusion [74]. However ad‐
ditional effects are via inhibition of glucagon and other peptides that increase post-prandial
mesenteric blood flow [75]. The mesenteric blood flow increases in variceal bleeding due to
the high protein gut loading from the intraluminal blood [76], and octreotide can reduce the
hormone-induced changes for up to 38 hours [77]. Somatostatin has fewer side effects than
terlipressin (0% vs. 10%) and a higher relative risk (1.62) for achieving initial control of
bleeding, but no survival benefit [78]. Thus vasoactive drugs are part of the initial therapy in
variceal haemorrhage and one of these drugs should be continued for 2- 5 days [2].
Prior to endoscopy a tamponading balloon such as the Sengstaken-Blakemore tube or Min‐
nesota tube can be considered, but the advent of 24-hour endoscopy services, vasoactive
drugs and TIPS has largely obviated the need for this intervention. Balloon tamponade
should be only be used in massive haemorrhage as a bridge to endoscopy [2]. Complications
of tube insertion include upper airway obstruction, inadvertent tracheal intubation, lower
oesophagus ulceration and even oesophageal rupture if the gastric balloon is wrongly inflat‐
ed in the oesophagus.
6. Endoscopic treament of acute oesophageal variceal haemorrhage
OGD is the investigation of choice in the diagnosis of variceal bleeding, and it offers endo‐
scopic therapeutic capability at the time. After general measures covered earlier in the chap‐
ter have been instituted in a patient with variceal bleeding, an urgent OGD should be
carried out within 12 hours of presentation [2]. Some experts recommend tracheal intubation
prior to OGD in all patients suspected of having variceal bleeding, to prevent aspiration of
blood into the airway. Endoscopic therapy for bleeding varices largely depends on the type
of varix that is bleeding – oesophageal or gastric. The mainstays of endoscopic therapy for
bleeding oesophageal varices include injection sclerotherapy and EVBL.
Endoscopic sclerotherapy for oesophageal varices has mainly been performed using the
sclerosant ethanolamine. Cyanoacrylate glue and thrombin have also been used. Sclerother‐
apy is done using a catheter with a retractable needle introduced through the endoscope’s
operating channel. Under endoscopic vision, the sclerosant is directly injected into the
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bleeding oesophageal varix. Local complications can include bleeding, stricture formation,
ulceration, oesophagitis, mediastinitis and oesophageal perforation.
Sclerotherapy controls active bleeding from oesophageal varices in 62-100% of patients and
is more effective than treatment with placebo, vasoactive therapy or balloon tamponade
[40]. A meta-analysis of 5 studies (Laine L, personal communication in Baveno IV consensus
statements [40]) of 251 patients comparing sclerotherapy with sham sclerotherapy, balloon
tamponade and/or vasopressive therapies showed significant benefits of sclerotherapy in
terms of initial haemostasis, in patient re-bleeding (OR=0.36, 0.21-0.62) and mortality
(OR=0.57, 0.33-0.98) [79-83]. A meta-analysis suggested that sclerotherapy was the “gold
standard” in acute variceal bleeding [84]. Despite the efficacy of endoscopic sclerotherapy
for actively bleeding oesophageal varices, endoscopic therapy has switched to EVBL. In part
this switch may have been extrapolated from the negative outcomes when sclerotherapy
was used as primary prophylaxis against variceal bleeding[57], but subsequent comparative
trials detailed below have pointed to a superiority of EVBL.
EVBL has evolved as the recommended standard of treatment for bleeding oesophageal
varices (Baveno IV guidelines) [40], and sclerotherapy is only recommended if ligation is
technically difficult. In a meta-analysis of 10 randomized controlled trials comparing EVBL
with sclerotherapy, there was an almost significant benefit of EVBL in achieving initial hae‐
mostasis compared to sclerotherapy (pooled relative risk of 0.53 with CI 0.28-1.01) [85]. In
one of the studies in the meta-analysis, HVPG increased significantly immediately after both
EVBL and sclerotherapy, but the HVPG remained elevated for the duration of the study (5
days) in the sclerotherapy group while returning to baseline levels by 48 hours after EVBL
group [86]. Another meta-analysis however found no difference in initial haemostasis rates
between sclerotherapy and EVBL (RR 1.1, 95% CI: 0.4-2.9) [87], but the actively bleeding pa‐
tients represented a small subset from larger trials, and were thus not truly from pure
randomized controlled trials in this population [40]. EVBL is associated with fewer adverse
effects than sclerotherapy. By consensus, EVBL is the preferred form of endoscopic therapy
for acute oesophageal variceal bleeding, although sclerotherapy is recommended in patients
in whom EVBL is not technically feasible.
Combination therapies of vasoactive drugs and direct endoscopic therapies have been stud‐
ied, with dual therapy conferring the potential benefits of pharmacological reduction in por‐
tal pressure together with the direct local haemostasing effects of either sclerotherapy or
EVBL. Combination is now recommended as a standard of care in oesophageal variceal
bleeding [2,40]. The combined effect of initial haemostasis was initially difficult to assess
due to heterogeneity of trials and definitions of immediate haemostasis. A meta-analysis of 4
trials including 559 patients, concluded that combined therapy was associated with a higher
rate of initial haemostasis than endoscopic therapy alone (88% v 76%, RR: 1.12, 95% CI:
1.02-1.23) [88]. Five-day haemostasis rates were studied in the Baveno IV consensus state‐
ments [40]. Pooling of results of 939 patients demonstrated that combination therapy ach‐
ieved greater haemostasis rates than endoscopic therapy alone (77% v 58%, RR: 1.28, 95% CI:
1.18-1.39) with a number needed to treat of 5 (95% CI 4-8) [89-96]. However no significant
differences were found in 5-day or 42-day mortality when combined vasoactive drug and
endoscopic therapy was compared to endoscopic therapy alone in 2 meta-analyses [88, 89].
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Two pooled randomized controlled trial results of combination therapy versus pharmaco‐
logical therapy alone showed combination therapy improved control of bleeding (RR: 3.1,
95% CI: 1.2-8.3) but with no influence on mortality [88, 89].
Figure 9. A bleeding gastric varix seen on retroflexion of the gastroscope (courtesy of Dr Adrian Stanley, Glasgow Roy‐
al Infirmary, 2006)
Figure 10. Self-expanding oesophageal metallic stent (courtesy of ELLA-CS, Hradec Kralove, Czech Republic)
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More recently self-expanding oesophageal metallic stents have been developed and used in
oesophageal variceal bleeds. They have been developed from their role in oesophageal ma‐
lignancy, and act by applying direct tamponading pressure to the distal oesophageal muco‐
sa and any associated varices. Stents were used in a pilot study in 20 patients who failed to
achieve haemostasis with pharmacological or endoscopic techniques [92]. Immediate hae‐
mostasis was achieved in 100% of these patients. Such stents seem a promising option in the
situation of refractory oesophageal haemorrhage, but further evaluation is needed.
Radiological therapies have been used in acute oesophageal variceal bleeding, with TIPS the
most commonly studied and available radiological modality. TIPS involves the placement of a
needle catheter via the transjugular route into the hepatic vein, and wedging it there under flu‐
oroscopic guidance. The needle is then advanced through the liver parenchyma to the intrahe‐
patic portion of the portal vein, creating a “side-to-side” anastomotic shunt. A stent is then
positioned across the liver, connecting the portal vein and hepatic veins, and allowing blood to
flow normally from the portal vein through the liver with a drop in the portal pressure. TIPS
was initially used as therapy for uncontrolled bleeding and achieved control of bleeding in
90-95% of patients and a 4-week survival of 50-60% [93]. Early TIPS placement has been shown
to have beneficial effect in patients with a HVPG > 20mmHg presenting with a variceal bleed
[94]. TIPS reduced treatment failures, hospital stay and 1-year mortality. Other studies have
confirmed the role of TIPS in variceal bleeding which cannot be controlled by endoscopy or
vasoactive drugs [95-97]. Complications of TIPS include haemorrhage, infection, intravascu‐
lar haemolysis and worsening of hepatic encephalopathy [95-97].
7. Endoscopic treatment of acute gastric variceal haemorrhage
Although less common than oesophageal variceal bleeding, gastric variceal haemorrhage is
often torrential with an associated high mortality (Figure 9). Re-bleeding is also common
with reported figures of up to 43-89% after a gastric variceal bleed [37, 98-101]. Gastric vari‐
ces can occur alone or in combination with oesophageal varices. They are often large and
located deep in the submucosa, making EVBL or injection therapy more difficult than that
for oesophageal varices. Gastric varices can remain quiescent and predicting which gastric
varix is likely to bleed can be difficult. Factors that are associated with a high risk of gastric
variceal bleeding include: red colour sign, large varices, or a rapid increase in size [102-104].
Therapeutic options for bleeding gastric varices include injection sclerotherapy, banding,
TIPS and other radiological interventions. Endoscopic sclerotherapy was first applied in the
treatment of a bleeding gastric varix in 1984 [105] and results in endothelial damage with
subsequent sclerosis of the varix. Variceal obliteration rates of 71.6% (mean follow up 24.2
+/-22.9 months) in gastric variceal bleeds treated with sclerotherapy have been reported
[101], but there are often high re-bleeding rates of 60-90% following sclerotherapy for gastric
varices [106, 107].
There are limited data on EVBL in the management of gastric variceal bleeding. EVBL can
be useful for varices extending from the oesophagus along the proximal lesser curve (Sarin
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GOV-1), but it is problematic for other types of gastric varices. High rates of gastric variceal
recurrence following EVBL may be due to a more superficial effect compared with obtura‐
tion therapy [108]. This, together with the technical difficulty of banding in a retroflexed en‐
doscope position has meant EVBL for gastric varices has largely been superseded by
obturation therapies using cyanoacrylate and thrombin injection.
Cyanoacrylate injection is effective for bleeding gastric varices, yet remains unapproved in the
USA. Injection of cyanoacrylate is not without complications including endoscope damage
due to blockage of the injection channel, detachment of the injection needle into a varix, cere‐
bral embolism, pulmonary embolism, splenic infarcts, mediastinitis and local abscesses. Al‐
though most reports of this therapy for gastric varices have limited follow-up, immediate
haemostasis rates of 92-100% have been reported with variable re-bleeding rates [108-113]. Cy‐
anoacrylate glue has been compared with ethanol injection in a randomised study with the for‐
mer showing faster rates of variceal obliteration with a smaller injection volume, improved
efficacy in control of acute gastric oesophageal variceal bleeding and reduced need for rescue
surgery [114]. Another randomised study concluded that the obliteration of gastric varices us‐
ing EVBL was more difficult and less effective than cyanoacrylate glue injection [115]. Early
haemostasis rates were 87% with cyanoacrylate and 45% with EVBL, and re-bleeding rates
were 31% and 54% respectively. Cyanoacrylate injection is also superior to beta-blockers in
preventing gastric variceal re-bleeding [116]. When 77 patients who had bled from gastric vari‐
ces were assigned to either beta-blockers or cyanoacrylate, those whose varices were injected
with cyanoacrylate had lower rebleeding rates (15% v 55%), and lower mortality (3% v 25%)
[116]. The addition of beta-blockers to cyanoacrylate therapy for secondary prevention after a
cyanoacrylate-treated index bleed, does not confer any additional benefit [117].
Thrombin is another obturation therapy advocated for acutely bleeding gastric varices in
some United Kingdom centres. It converts fibrinogen to a fibrin clot and causes platelet ag‐
gregation [118]. There have been small case-series of its use with haemostasis rates between
70-100% using bovine thrombin [119-122]. However there was concern that this material of
bovine origin might present a potential risk of prion transmission. Short-term small studies
of human-derived thrombin have demonstrated initial haemostasis rates of 100% but a high
mortality from re-bleeding [123-125].
Interventional radiological procedures for the treatment of gastric varices include TIPS
[126-128] and Balloon-occluded Retrograde Transvenous Obliteration (BRTO) [127-129] as
salvage or rescue therapy when obturation therapy fails. BRTO is an interventional radio‐
logical technique used mostly in Far East Asia for gastric variceal bleeding. The gastro-renal
shunts often seen in such patients can be occluded with sclerosant via a balloon catheter ap‐
proach via the left renal vein [129]. BRTO may become an alternative to TIPS in patients
with active gastric variceal bleeding in whom a gastrorenal shunt is present [130].
Current Baveno V guidelines [2] suggest early TIPS within 72 hours (ideally < 24 hours) in
patients at high risk of treatment failure (Child-Pugh class C < 14 points or Child-Pugh class
B with active bleeding) after initial pharmacology and endoscopic therapy in patients with
variceal bleeding. This recommendation is derived from the pivotal study from Barcelona in
which 63 cirrhotic patients with variceal bleeding were treated with vasoactive drugs and
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endoscopic therapy and then randomised to treatment with a TIPS within 72 hours (“early-
TIPS”) or else continuation of vasoactive drugs for 3 to 5 days followed by non-selective be‐
ta-blockers and long-term EVBL with insertion of a TIPS only if required as a rescue therapy
[132]. Rebleeding or failure to control bleeding occurred in only 1 of the “early-TIPS” pa‐
tients and in 14 of the vasoactive drug/EVBL group (p<0.001). Overall mortality was lower
in the “early-TIPS” group (12 patients versus 4, p = 0.01) with 1-year survival 61% in the vas‐
oactive drug/EVBL group versus 86% in the “early-TIPS” group (p <0.001).
8. Prevention of rebleeding (secondary prophylaxis)
The improvement in survival from index variceal bleeds using the therapies discussed has
focussed attention on prevention of rebleeding. 60-80% of patients who bleed from varices
will rebleed if not treated [18, 40,133, 134], and the risk of rebleeding is greatest in the first 10
days (131,132), during which 50% of those who are going to rebleed, do so. The risk of re‐
bleeding gradually falls over the first month when an additional 10% rebleed [133, 134]; the
risk after the first six weeks then plateaus out. Despite the advent of endoscopic therapies
and early pharmacological therapies, rebleeding rates are still higher early on, with factors
predictive of early rebleeding /treatment failure at 5 days including: active bleeding at index
endoscopy, severity of liver disease (Child-Pugh class), severity of bleed, and severity of
portal hypertension [132, 135]. HVPG is one of the best predictors of identifying those who
will re-bleed. After an index variceal bleed, a reduction of HVPG to less than 12mm Hg or
by at least 20%, reduces the risk of rebleeding from 46-65% to 0.13% [136]. HVPG measure‐
ment is usually limited to specialist centres.
Strategies to prevent rebleeding historically included surgical portocaval shunts, but cur‐
rently involve pharmacological and endoscopic therapies. Pharmacological therapies in‐
clude non-selective beta-blockers, and endoscopic therapies include sclerotherapy or EVBL.
Beta-blockers significantly reduce rebleeding rates and improve survival at 2 years when
compared to placebo [24,137]. Factors associated with a risk of rebleeding in patients treated
with beta-blockers included a lack of compliance or a lack of reduction of heart rate [138].
Injection sclerotherapy reduces the risk of rebleeding from 65% to 35% but does not appear
to reduce overall mortality and is associated with complications such as oesophageal ulcera‐
tion [40]. When sclerotherapy was compared with beta-blockers there was less rebleeding in
the sclerotherapy group, but significantly more side effects and no impact on mortality [136,
139]. EVBL has been shown to be superior to sclerotherapy in reducing the risk of rebleed‐
ing to a greater level with fewer side effects [87]. The combination of EVBL and sclerothera‐
py was no more effective than EVBL alone [140]. A combination of beta-blocker therapy
with either EVBL or sclerotherapy has been found to reduce all bleeding, rebleeding from
varices and variceal recurrence but not mortality, when compared to any single modality of
therapy [141]. TIPS has been studied in early rebleeding with excellent results as mentioned
previously in the chapter [132].
In summary, current Baveno V guidelines [2] suggest secondary prophylaxis should start on
day 6 of the index bleed. A combination of beta-blocker therapy and EVBL is recommended
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over either treatment alone as there are lower re-bleed rates with combination therapy. In
patients who are unwilling to have EVBL, beta-blockers with ISMN is recommended [2]. In
patients intolerant of beta-blockers, EVBL alone is recommended. In patients who re-bleed
despite endoscopic and pharmacological therapies, TIPS is recommended. Transplantation
should be considered in those who are appropriate candidates.
9. Conclusions
Variceal haemorrhage remains a life-threatening emergency, and a cause of decompensation
of patients with portal hypertension or cirrhosis. Prevention of the development of portal
hypertension where possible remains key in halting the development of oesophageal or gas‐
tric varices. However when portal hypertension has developed, it is important to identify
those at risk of varices and enter them into a screening programme. Those found to have
varices should be offered primary prophylaxis if required. Once a varix bleeds, urgent spe‐
cialist care is required to potentially save life. In addition to fluid and blood resuscitation to
stabilise conditions before endoscopy, vasoactive medications to reduced portal pressure
and antibiotics should be administered. At urgent endoscopy performed by an experienced
endoscopist, EVBL is the preferred endoscopic technique to achieve haemostasis in oesopha‐
geal variceal haemorrhage, and injection of cyanoacrylate glue is the preferred endoscopic
technique to achieve haemostasis in gastric variceal haemorrhage. If endoscopic therapy is
difficult, or does not halt the bleeding then TIPS can be performed, although self-expanding
tamponading stents may be useful in refractory oesophageal variceal bleeding and BRTO
may be useful in refractory gastric variceal bleeding. Survivors of variceal bleeding should
receive secondary prophylaxis with beta-blocker medication, together with EVBL in the case
of oesophageal varices.
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